Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,870,000 shares, a drop of 17.0% from the December 31st total of 4,660,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is presently 2.3 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Trevi Therapeutics in the second quarter worth approximately $61,000. Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics in the third quarter worth $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $67,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after buying an additional 11,450 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Up 1.0 %

TRVI traded up $0.04 during trading on Friday, hitting $3.94. The company’s stock had a trading volume of 383,085 shares, compared to its average volume of 504,529. The business’s 50 day simple moving average is $3.67 and its 200-day simple moving average is $3.25. The firm has a market cap of $302.87 million, a PE ratio of -8.95 and a beta of 0.87. Trevi Therapeutics has a one year low of $1.35 and a one year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period in the previous year, the firm posted ($0.08) earnings per share. Equities research analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Analyst Ratings Changes

TRVI has been the subject of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. B. Riley reissued a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a report on Monday, October 7th. HC Wainwright raised their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.